This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Noxxon Pharma Ag. Active years: 2011.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2011
Title: Thorsten Ruppert: Innovator in Nucleic Acid Technology
Introduction
Thorsten Ruppert is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of biotechnology, particularly in the development of nucleic acid technologies. His work focuses on innovative solutions that address critical health challenges.
Latest Patents
Thorsten Ruppert holds a patent for "CGRP binding nucleic acids." This invention relates to an antagonist for CGRP and amylin, where the antagonist is a nucleic acid that binds to CGRP or amylin. The nucleic acid preferably comprises an L-nucleotide, showcasing Ruppert's expertise in molecular biology and therapeutic applications.
Career Highlights
Ruppert is currently associated with Noxxon Pharma AG, a company dedicated to advancing innovative therapies. His role at Noxxon Pharma AG allows him to leverage his expertise in nucleic acid technology to contribute to the development of novel treatments.
Collaborations
Throughout his career, Thorsten Ruppert has collaborated with talented professionals, including Elisabeth Moyroud and Clemens Gillen. These collaborations have fostered a dynamic environment for innovation and research.
Conclusion
Thorsten Ruppert's work in nucleic acid technology exemplifies the impact of innovative thinking in biotechnology. His contributions continue to pave the way for advancements in therapeutic solutions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile